Pfizer, Mylan enter into agreement to develop, commercialise generic drugs in Japan

Pfizer and Mylan on Wednesday announced that they have signed a definitive agreement to establish an exclusive long-term strategic collaboration to develop, manufacture, distribute and market generic drugs in Japan. The collaboration, the financial terms of which were not disclosed, will include a portfolio of more than 350 marketed products across a broad range of therapeutic categories, as well as more than 125 additional products in development.

Under the terms of the agreement, Pfizer will commercialise the combined generics portfolio, while Mylan's role will primarily consist of managing operations, including research and development and manufacturing. Any products sold under the collaboration will be marketed under the Pfizer brand but with joint labeling. The companies, which will share the costs and profits resulting from the collaboration, will each continue to operate independent entities in Japan.

To read more Top Story articles, click here.